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A b s t r a c t
Background: Implantable cardioverter-defibrillator (ICD) therapy has been proven effective in the prevention of sudden cardiac 
death, but data on outcomes of ICD therapy in the young and otherwise healthy patients with long QT syndrome (LQTS) are limited.
Aim: We sought to collect data on appropriate and inappropriate ICD discharges, risk factors, and ICD-related complications.
Methods: All LQTS patients implanted with an ICD in 14 centres were investigated. Demographic, clinical, and ICD therapy 
data were collected.
Results: The study included 67 patients (88% female). Median age at ICD implantation was 31 years (12–77 years). ICD 
indication was based on resuscitated cardiac arrest in 46 patients, syncope in 18 patients, and malignant family history in 
three patients. During a median follow-up of 48 months, 39 (58%) patients received one or more ICD therapies. Time to first 
appropriate discharge was up to 55 months. Inappropriate therapies were triggered by fast sinus rhythm, atrial fibrillation, and 
T-wave oversensing. No predictors of inappropriate shocks were identified. Risk factors for appropriate ICD therapy were:  
(1) recurrent syncope despite b-blocker treatment before ICD implantation, (2) pacemaker therapy before ICD implantation, 
(3) single-chamber ICD, and (4) noncompliance to b-blockers. In 38 (57%) patients, at least one complication occurred.
Conclusions: ICD therapy is effective in nearly half the patient population; however, the rates of early and late complica-
tions are high. Although the number of unnecessary ICD shocks and reimplantation procedures may be lowered by modern 
programming and increased longevity of newer ICD generators, other adverse events are less likely to be reduced.
Key words: device recalls, ICD outcome, implantable cardioverter-defibrillator, lead dysfunction, long QT syndrome, risk factors
Kardiol Pol 2018; 76, 12: 1687–1696
www.kardiologiapolska.pl
Kardiologia Polska 2018; 76, 12: 1687–1696; DOI: 10.5603/KP.a2018.0177 ISSN 0022–9032
INTRODUCTION
Inherited non-syndromic long QT syndrome (LQTS) is 
characterised by QT interval prolongation on the surface 
electrocardiogram and a risk for life-threatening ventricular 
arrhythmias in the absence of structural heart disease. In 
the context of LQTS, general agreement exists that patients 
presenting with aborted sudden death have a higher risk of 
recurrent arrhythmic events and should receive an implantable 
cardioverter-defibrillator (ICD), whereas more controversy 
surrounds ICD implantation in the primary prevention of 
sudden cardiac death (SCD) [1, 2]. 
No randomised clinical trial has ever been conducted 
on ICDs in LQTS patients, thus registry data on outcomes 
of ICD therapy in the young and otherwise healthy popula-
tion of LQTS patients are still of importance. We conducted 
a multicentre study to collect information on appropriate and 
inappropriate ICD therapies, risk factors, and complication 
rates in the long-term follow-up of primary and secondary 
preventive ICD therapy in LQTS patients.
METHODS
Patient population
Patients were included in the study if they had a documenta-
tion of corrected QT interval (QTc) prolongation > 450 ms 
(men) and > 460 ms (women) in the absence of QT-prolonging 
drugs and if they met at least one of the following criteria [3]: 
(i) history of aborted SCD; (ii) history of recurrent syncope 
with or without concomitantly recorded torsade de pointes 
(TdP); (iii) malignant family history of sudden death (≥ two 
sudden deaths in close relatives < 40 years old).
A total of 74 patients referred as suspected LQTS cases 
were screened. Of these, seven patients were excluded be-
cause they were subsequently diagnosed with polymorphic 
catecholaminergic ventricular tachycardia (VT; n = 3), myo-
carditis (n = 2), drug-induced QT prolongation (n = 1), and 
idiopathic ventricular fibrillation (VF; n = 1). The remaining 
67 patients were included in further analysis.
The following clinical data were collected in all 14 par-
ticipating centres: circumstances of diagnosis and indications 
for ICD implantation, age at first symptoms and at diagnosis, 
sex, family history of LQTS and SCD (< 40 years of age), and 
the efficacy of previous treatment. Left cardiac sympathetic 
denervation was not performed in any patient.
Electrocardiographic definitions
Long QT syndrome was diagnosed when QTc interval pro-
longation > 440 ms in men and > 460 ms in women was 
recorded in the absence of QT-prolonging drugs. QT measure-
ments were made in leads II and V5. Corrections were made 
using Bazett’s formula.
ICD implantation
A single- or dual-chamber ICD was implanted since Decem-
ber 1995 according to the investigator’s preference. The 
decision was based on the presence of concomitant pacing 
indication and/or on the presence of supraventricular arrhyth-
mias. Implantation was performed with a non-thoracotomy 
transvenous lead system in all patients. One patient had an 
abdominally placed ICD; in other patients the device was im-
planted pectorally. The programming was left to the individual 
investigator’s choice; however, due to the long time span of 
the study, in many of the first implants the commonly used 
setting for VF detection was 12 of 16 intervals. 
ICD follow-up
The patients were routinely followed at one, three and six 
month(s) after implantation, then every six months regularly, 
as in the case of shock therapy. The therapy was classified as 
appropriate if analysis of the onset, stability, QRS morphol-
ogy (if available), and termination of the tachycardia with 
ICD therapy suggested the ventricular origin of arrhythmia. 
Inappropriate shocks were defined as those delivered in the 
absence of ventricular arrhythmia. Device effectiveness was 
assessed by the number of patients who had an appropriate 
defibrillation after ICD implantation: only the first appropriate 
shock was considered for analysis. Electric storm was defined 
as ≥ three appropriate ICD shocks in 24 h, and clustered ICD 
therapies as ≥ three either appropriate or inappropriate ICD 
therapies in 24 h.
Statistical analysis
Statistical calculations were performed using the Statistica PL 
software (StatSoft, Inc., Tulsa, OK, USA). Data are presented 
as either mean ± standard deviation or median (interquar-
tile range), depending on data type and distribution on the 
interval scale. We analysed the demographic, clinical, and 
therapy-related data. The clinical data included previous 
cardiac arrest, documented TdP, prior syncope and recurrent 
syncope despite b-blocker treatment, QTc interval in leads II 
and V5, LQT locus, Schwartz score, family history of SCD, as 
well as age at first symptoms and at ICD implantation. The 
therapy-related data included personal history of LQTS treat-
ment (b-blockers, pacemakers), b-blocking therapy after ICD 
implantation, and ICD-related data (ICD type, R-wave am-
plitude on intracardiac electrogram, defibrillation threshold).
Normal distributions were verified with W Shapiro-Wilk 
test. Intergroup differences were examined using Student t 
test, Mann-Whitney U test, and the c2 test or Fisher exact 
test when necessary. The Kaplan-Meier method was used 
for the presentation of appropriate and inappropriate ICD 
intervention-free periods. Log-rank method was used to 
investigate significant differences between the groups in the 
time to the first event (appropriate or inappropriate shock). 
Parameters expressed as continuous data were categorised, 
and borderline values for each category were as follows: 
age at first symptoms and at ICD implantation — 40 years, 
QTc — 500 ms; number of syncopal episodes — three; 
Schwartz score — 4; R-wave amplitude — 5 mV, defibrilla-
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tion threshold (DFT) — 10 J. Subsequently, the variables with 
a p-value < 0.05 in the log-rank analysis were entered in the 
multivariable Cox regression analysis for proportional hazards 
assumptions. Significance was assumed at p < 0.05.
RESULTS
Patient characteristics
Baseline characteristics of the 67 patients are shown in Table 1. 
The mean age at ICD implantation was 31.4 years (range, 
12–77 years). At the time of implantation, 45 (67%) patients 
were ≤ 40, and five patients were ≥ 60 years old (Fig. 1). The 
median age at first symptom was 24 years (range, 8–77 years), 
and the median Schwartz score was 4 (range, 2–7). A total of 
22 (33%) patients were treated with b-blockers before ICD 
implantation. In 14 patients, drugs were ineffective in prevent-
ing syncope or cardiac arrest. Five patients had pacemakers 
implanted during childhood, but symptoms recurred despite 
b-blocker treatment and pacing in four of them. In seven pa-
tients, cardiac arrest was complicated by neurological defects.
Six patients were implanted with pacemakers in the years 
1985 to 2000 because of multiple syncopal episodes in the 
course of LQTS in four patients, syncope with sinus bradycar-
dia in one patient (in whom LQTS diagnosis was overlooked), 
and a strong family history of SCD in a 10-year-old LQTS boy 
in the year following the death of his nine-year-old brother. 
There were AAI (three cases), DDD (two cases), and VVI (one 
case) pacemakers used. None of the patients was diagnosed 
with atrioventricular (AV) conduction disturbances. All patients 
were re-implanted with ICDs when the ICD became available 
as a measure of primary prevention of SCD in Poland, or when 
they reached secondary prevention criteria (three patients). At 
ICD implantation left ventricular ejection fraction was normal. 
ICD implantation
A total of 46 (69%) patients were cardiac arrest survivors. In 
21 patients, an ICD was implanted in primary prevention of 
SCD; in 18 of those 21 patients, it was implanted because 
of syncope or recurrent syncope despite b-blocker/pace-
maker therapy. Three other patients had strong positive 
family histories of sudden death in at least two close family 
members < 40 years of age.
A dual-chamber device as a first ICD was implanted in 
32 (48%) patients. Median DFT at first ICD implant was 10 J 
(range, 3–20 J). There were no significant differences in DFT 
at subsequent ICD reimplantations, except for one case in 
which high DFT at reimplantation prompted the insertion of 
a high-energy device. 
Follow-up
The median follow-up was 47.8 months, with a range from 
one month to 11 years. In 25% of patients the follow-up 
was ≤ 25.6 months, and in 25% it was ≥ 68.4 months. One 
Figure 1. Age at implantable cardioverter-defibrillator implan-
tation in long QT syndrome patients implanted in the primary 
and secondary prevention of sudden cardiac death
Table 1. Baseline characteristics (clinical history) of the study 
patients (n = 67)
Clinical history:
Female sex 59 (88)
Age at first cardiac event [years] 24 (8–77)
Age at implantation [years] 31 (12–77)
QTc II [ms] 482 ± 35 
QTc V5 [ms] 483 ± 30
Schwartz score 4 (2–7)
SCD in family history 12 (18)
LQT1/LQT2/LQT3 locus 7/15/4
Indications for ICD:
Cardiac arrest survivor 46 (69)
Syncope or recurrent syncope despite treatment 18 (27)
Malignant family history 3 (4.5)
b-blockers before ICD implantation 23 (34)
Prior pacemaker implantation 6 (9)
ICD parameters at implantation:
ICD type (single-/dual-chamber) 35/32
R-wave [ms] 10 (2–30)
Defibrillation threshold [J] 10 (3–20)
Data are presented as number (percentage), mean ± standard devia-
tion, or median (interquartile range) depending on data type and 
distribution on the interval scale. ICD — implantable cardioverter- 
-defibrillator; LQTS — long QT syndrome; SCD — sudden cardiac 
death; QTc — corrected QT interval
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patient was lost to follow-up and one other patient did not 
attend routine check-ups and, after receiving the necessary ex-
plantation of an ICD system because of lead failure and battery 
depletion, refused ICD reimplantation and further treatment. 
All other patients presented for scheduled follow-up visits. 
Appropriate ICD therapies
Appropriate ICD therapies occurred in 30 patients (45%) 
(Fig. 2). In this group, 23 (77%) patients were cardiac arrest 
survivors, whereas the remaining patients were implanted 
due to syncope (six) or malignant family history (one). The 
majority of patients (80%), including six primary prevention 
patients, took b-blockers at the time of the arrhythmic episode 
triggering ICD intervention. Patients with appropriate therapy 
had 254 ICD discharges (range, 1–66 therapies); median time 
to first ICD therapy was nine months (range, 0.4–55 months). 
Characteristics of patients with and without appropriate ICD 
therapies are presented in Table 2.
Risk factors for appropriate ICD therapy in survival analy-
sis were: (i) recurrent syncope despite b-blocker treatment be-
fore ICD implantation, (ii) pacemaker therapy before ICD im-
plantation, (iii) single-chamber ICD, and (iv) noncompliance to 
b-blocker therapy. However, in the Cox analysis, only the last 
three were confirmed to be independent risk factors (Table 3). 
A
Figure 2. Kaplan-Meier curves for appropriate (A) and 
inappropriate (B) implantable cardioverter-defibrillator (ICD) 
therapy-free survival analysis
B
Table 2. Characteristics of patients with and without appropriate implantable cardioverter-defibrillator (ICD) therapies
Appropriate ICD therapy No ICD therapy p
Clinical history:
Female sex 27 (90) 32 (87) 0.72
Age at first cardiac event [years] 20 (8–77) 27 (9–72) 0.58
Age at implantation [years] 30 (16–77) 33 (12–72) 0.48
QTc II [ms] 477 ± 36 485 ± 35 0.44
QTc V5 [ms] 482 ± 37 484 ± 24 0.82
Schwartz score 4 (3–7) 4 (2–6) 0.75
SCD in family history 5 (17) 6 (16) 0.61
LQT1/LQT2/LQT3 locus 1/7/0 6/8/4
Indications for ICD:
Cardiac arrest survivor 23 (77) 23 (62) 0.20
Syncope or recurrent syncope despite treatment 11 (37) 4 (11) 0.013
Malignant family history 7 (23) 13 (35) 0.29
Dual-chamber ICD 9 (30) 23 (62) 0.0088
b-blocker treatment 25 (86) 33 (100) 0.043
Data are presented as number (percentage), mean ± standard deviation or median (interquartile range), depending on data type and distribution. 
Abbreviations — see Table 1
Table 3. Risk factors for appropriate implantable cardioverter-
-defibrillator (ICD) therapy
Variable Hazard ratio 95% CI p
Pacemaker before ICD 6.43 2.18–18.91 0.0007
ICD-VVI 2.51 1.12–5.62 0.0254
Concomitant BB therapy 0.19 0.06–0.65 0.0080
Only parameters that were shown to be significant in survival analysis 
were included in Cox analysis. BB — b-blocker; CI — confidence interval
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QTc, sex, and locus were not shown to be risk factors. The 
analysis of independent risk factors for secondary prevention 
patients showed that the presence of the pacemaker prior 
to an ICD implantation was the only independent risk fac-
tor, with hazard ratio 5.29 and 95% confidence interval (CI) 
1.032–27.09; p = 0.046. However, due to the low number 
of pacemaker patients the CI is very wide. When the ICD 
patients with an appropriate shock were compared to those 
without, there were no differences in age, sex, QTc interval, 
age at first LQTS symptom, Schwartz score, or personal and 
family history of SCD. However, patients with appropriate ICD 
therapy had more syncopal episodes before ICD implanta-
tion despite b-blocking treatment (37% vs. 11%, p = 0.013), 
they were less compliant to b-blockers after ICD implantation 
(86% vs. 100%, p = 0.043), and they more frequently had 
single-chamber ICDs (70% vs. 38%, p = 0.0088) (Table 2).
Inappropriate therapies
In 14 (21%) patients, 48 inappropriate therapies occurred 
(Fig. 3). Of these 14 patients, 10 were cardiac arrest survivors. 
Figure 3. An episode of ventricular tachyarrhythmia in a long QT syndrome patient, terminated by an implantable cardioverter-
-defibrillator shock
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Inappropriate interventions were triggered by fast sinus rhythm 
(SR; six), atrial fibrillation (AF; four), T-wave oversensing 
(three), myopotentials (one), and lead failure (one patient). In 
one case, the ICD fired for non-sustained polymorphic VT; the 
majority of patients (92%) were on b-blockers at the time of 
inappropriate ICD firing. The median time to first inappropri-
ate therapy was 3.6 months (range, one day – 24.3 months). 
No independent risk factors for inappropriate therapy were 
found. Data for patients with inappropriate discharges are 
shown in Table 4.
Freedom from (in)appropriate shocks  
and overall survival
In an attempt to estimate the risk of recurrent life-threatening 
ventricular arrhythmias and thus the potential impact of ICD 
on survival, freedom from appropriate ICD therapy was es-
timated (Fig. 2). No difference in the frequency of first ICD 
therapy depending on indications for ICD or sex was found. 
There were no differences in time to first appropriate and 
inappropriate ICD therapy. 
Primary prevention of sudden death
Among 18 patients in whom an ICD was implanted because 
of syncope, six had appropriate ICD discharges despite 
b-blocker therapy. Although significant family history was the 
sole indication for ICD insertion in three patients representing 
two families with particularly malignant phenotype, primary 
prevention patients more frequently had family history of 
sudden death (33.3% vs. 9.5%, p = 0.017), as compared 
to patients who received an ICD in secondary prevention of 
SCD. Primary prevention patients also had more syncopal 
spells before ICD implantation (90% vs. 65%, p = 0.027). 
Clustered ICD therapies
Six (8.9%) patients presented with 14 episodes of clustered 
ICD shocks. Arrhythmic storm (≥ three episodes of VT/VF 
within 24 h) occurred in five (7.7%) patients, recurring from 
two to three times in four of them during the period under 
study. Other episodes of clustered ICD shocks were caused 
by AF (three), T-wave oversensing (one), or lead failure (one). 
Interestingly, in a female patient in her sixth decade of life, 
six episodes of multiple ICD shocks occurred. These were 
triggered initially by ventricular tachyarrhythmias, but, within 
a few years, paroxysmal AF developed, which is known to 
cause clustered ICD shocks. After unsuccessful treatment 
with AV node blocking agents, AV junction ablation was 
performed, and a dual-chamber ICD was implanted in the 
patient, revealing several episodes of AF and a separate run 
of ventricular tachyarrhythmia.
Complications and re-interventions
Early complications, which occurred during the first month 
in nine (13%) patients, were pneumothorax in four, dislodg-
ment of atrial and/or ventricular lead in six, and infection of 
the ICD pocket in one patient. Late complications (occurring 
later than one month after implantation) included ICD mal-
function (14 cases of early battery depletion, system errors in 
13 patients), lead failure requiring reimplantation of a new 
lead (13 cases in nine patients), pocket and/or lead infection 
that required both lead and generator replacement (three 
Table 4. Data of patients with inappropriate implantable cardioverter-defibrillator (ICD) therapy




M.J. 16 – D SR +
M.P. 20 HERG D SR +
S.M. 35 SCN5A D SR +
H.Z. 71 HERG V AF +
P.R. 17 KCNQ1 V TWO +
E.S. 21 HERG D SR, myopotentials +
J.S. 37 – D SR +
E.G. 45 – D TWO +
H.K. 29 – D Ventricular lead failure -
E.P. 35 – D SR +
A.B. 18 – D AF +
K.M. 20 – V TWO -
Z.Z. 56 – V AF +
H.K. 48 KCNQ1 V, then D AF, nsVT +
AF — atrial fibrillation; D — dual-chamber ICD; nsVT — non-sustained ventricular tachycardia; SR — sinus rhythm; TWO — T-wave oversensing; 
V — single-chamber ICD
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patients), and high defibrillation threshold at reimplantation. 
Failure of the defibrillation lead was recognised in six patients, 
and dysfunction of the atrial lead or both leads was recog-
nised in one and two patients, respectively. In one subject, 
the defibrillation lead was broken twice. There was one case 
of late dislodgement of the defibrillation lead with a perfora-
tion of the right ventricle, which was diagnosed three years 
after ICD implantation, being the cause of thoracic surgery 
in a 19-year-old man. Overall, 38 (57%) patients had at least 
one complication, such as inappropriate ICD intervention, 
clustered ICD therapy, dislodgement or malfunction of an ICD 
lead, or an infection-related event (scheduled ICD replace-
ments were not included). A total of 108 ICDs were implanted 
in the 67 patients studied: one device in 34 patients, two 
in 26 patients, three in five patients, and four in three pa-
tients. In 19 (28%) patients, 21 procedures were performed 
due to elective replacement indications. In four patients, ICD 
was upgraded to ICD-DDD, whereas two patients, who had 
dual-chamber ICDs previously, received the ICD-VVI due to 
atrial lead failure or infective endocarditis.
DISCUSSION
The present study is the first multicentre study to analyse the 
outcome, complications, and risk factors of ICD therapy in LQTS 
patients in Poland. It demonstrated that ICD is effective in nearly 
half of patients; however, the early and late complication rates 
during a median follow-up of 48 months are high. The observed 
frequency of re-interventions and inappropriate discharges pro-
vide evidence against a more aggressive implanting approach.
Indications for ICD implantations
Contrary to other registries, in which cardiac arrest survivors 
constituted less than 50% of implanted LQTS patients, 69% 
of our patients had cardiac arrest before ICD implantation 
[4–7]. This is probably the reason for the higher rate of ap-
propriate ICD shocks, which occurred in 45% of patients in 
our study. It is likely, however, that many of these shocks could 
be prevented by longer detection settings.
Among primary prevention patients, three were implanted 
with ICDs because of a strong family history (e.g. death of five 
family members < 40 years of age within one family). None 
of these patients experienced appropriate ICD shocks during 
long-term follow-up, while one of them suffered from inap-
propriate shocks caused by an ICD lead failure. In the United 
States a strong family history was considered an indication for an 
ICD implantation. However, in LQTS, the clinical usefulness of 
family history has never been confirmed (as opposed to hyper-
trophic cardiomyopathy) [8–10]. Our observation confirms that, 
even in patients with very severe family history, empathy-driven 
decisions on ICD implantations should be avoided. 
Appropriate discharges
In our study, ICD therapy was shown to be effective, deliver-
ing one or more potentially lifesaving therapies in 45% of 
patients. Interestingly, when compared to other genetically 
determined arrhythmogenic disorders, the observed rate of 
ICD therapies is the highest [2–5], except for patients with 
arrhythmogenic right ventricular cardiomyopathy, in whom 
similar ICD intervention rates have been shown [11]. The 
frequent appropriate ICD therapies observed in our study 
may be related to the relatively high number of human 
Ether-a-go-go-related Gene (hERG) patients who used to 
have numerous cardiac events despite b-blocker therapy 
[12]. The predominance of secondary prevention patients, 
who usually were probands, may also be responsible for the 
rate of ICD interventions, because probands were shown to 
be more symptomatic [13]. Noncompliance with b-blockers 
may be another reason for high arrhythmia rate because only 
87% of patients took b-blockers at the time of the arrhythmic 
episode, which demonstrates the importance of educating 
LQTS patients on how to be compliant with b-blockers, even 
if an ICD is implanted. In contrast, it is well appreciated that 
TdP is not invariably fatal, and, even if the longest possible 
detection time is programmed, it cannot be excluded that 
arrhythmia would terminate spontaneously if not treated.
We tried to identify the potential predictors of appropriate 
shocks. However, the known risk factors of SCD, including 
sex and QTc [14], did not predict the occurrence of appropri-
ate shocks, whereas the number of genotyped patients was 
too small to impact statistics. In the Cox analysis pacemaker 
therapy before ICD implantation, single-chamber ICD, and 
noncompliance to b-blocker therapy after implantation were 
shown to be independently associated with the risk of ap-
propriate ICD therapy. Before the ICD era, pacemakers were 
used mainly in symptomatic LQTS patients or were implanted 
instead of ICDs in highly symptomatic children. This finding 
may show that the relatively more symptomatic course of the 
LQTS during childhood still confers a risk in adults. When the 
relation between single-chamber ICD and appropriate ICD 
shocks is considered, a pro-arrhythmic effect of VVI pacing in 
LQTS patients cannot be excluded. Because an analysis of the 
initiating mechanism was not available in our study, the clinical 
significance of this assumption requires further investigation. 
However, since episodes of TdP are frequently triggered by 
short-long-short sequences, this finding may point to a lack 
of rhythm stabilisation in VVI patients. 
Family history of SCD, while important for establishing 
the diagnosis, is not considered helpful for risk stratification 
[10]. As we have shown, malignant family history strongly 
impacts decision-making about ICD insertion; as many as 
33.3% of primary prevention patients had a family history 
of sudden death, compared to 9% of secondary prevention 
patients (p = 0.02). Furthermore, in three patients, significant 
family history was the only indication for ICD implantation, 
whereas, in one of these patients, multiple appropriate ICD 
shocks occurred during follow-up.
It is important to stress that time to a first appropriate 
discharge was up to 55 months. Considering the average life 
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of ICD batteries, this finding is of clinical relevance for patients 
who may suffer from ICD-related adverse effects and reject 
ICD replacement on the basis of its alleged futility.
Avoidance of ICD shocks
The percentage of patients receiving inappropriate therapy in 
this study was 21%, which is similar to the data observed in 
other young ICD populations [11, 15, 16]. Inappropriate shocks 
were triggered mainly by fast SR, atrial arrhythmias, and T-wave 
oversensing. Johnson et al. [17] documented that AF occurs in 
around 2% of LQTS patients, and in our study, AF triggered the 
ICD response in 6% of patients. The high rate of inappropriate 
therapies due to the oversensing of SR or AF demonstrates further 
that ICD therapy should be combined with b-blocker treatment.
In the context of LQTS, the programming of therapeutic 
zones and therapies constitutes an important concern. The 
PainFREE trial has shown that activating antitachycardia pacing 
(ATP) for fast VT is effective in 81% of the episodes, thereby 
significantly reducing the number of appropriate shocks [18]. It 
is unknown, however, whether ATP can convert polymorphic 
VT such as TdP, although it seems unlikely because of the rapid 
rate and suspected disorganisation of TdP. The question of 
how many shocks could be prevented by using ATP in a VF 
window merits further investigation. Moreover, some pacing 
algorithms used in modern pacemakers may have proarrhyth-
mic effects [19–21]. Thus, universal recommendations on ICD 
and pacemaker programming are needed.
Electrical storms
It is well appreciated that, in LQTS, an adrenergic drive dur-
ing exercise or strong emotions may trigger life-threatening 
arrhythmias [22]. It was speculated that ICD shock via catecho-
lamine release may increase susceptibility to arrhythmias and 
subsequent ICD shocks leading to electrical storms. Indeed, 
this phenomenon is observed in LQTS patients. In the study 
by Mönning et al. [5], as many as 18.5% of 27 ICD patients 
experienced electrical arrhythmic storms despite b-blocker 
therapy. In our study, arrhythmic storms were less prevalent, 
occurring in 9% of patients. Notably, electrical storms tended 
to recur in the same patients, showing that a specific genetic 
susceptibility may underlie these adverse effects.
Complications
Our study confirms that lead longevity is one of the major 
problems in patients with a long life expectancy, which is 
in accordance with the results of other studies of young pa-
tients [15, 16, 23, 24]. In young and active patients, long life 
expectancy results in increased numbers of lead extractions 
and replacements, reaching 13.4% of patients in our study. 
This is most clearly shown in our patient in whom lead failure 
required as many as three defibrillation leads to be implanted. 
Not only does lead malfunction increase the number of surgi-
cal re-interventions, but it may also result in life-threatening 
conditions such as ICD system infection or right ventricular 
perforation, increasing significantly the morbidity of LQTS-ICD 
patients (in our study, 4.5% and 1.5%, respectively).
Another important concern is the high frequency of ICD 
reimplantations, which were caused either by expected end of 
life, ICD malfunction, ICD system and/or pocket infection, or 
high DFT, and which occurred in 34 (51%) patients. In the future, 
improvement of the battery’s technical capability and prevention 
of inappropriate shocks may reduce the need for re-interventions, 
which may subsequently decrease the accompanying complica-
tions. Of particular importance is a cluster of device recalls that 
occurred during the period under study, increasing the rate of 
device re-interventions. This is not expected to be repeated 
in future years; however, it underscores the concern that this 
therapy is not without unexpected risk. Although the number 
of unnecessary ICD shocks and reimplantation procedures may 
be lowered by modern programming and increased longevity of 
newer ICDs, other adverse events are less likely to be reduced. 
In some, but not all, LQTS patients a subcutaneous ICD may be 
an option to minimise the risk of complications [25, 26].
This study is based on an observational multicentre reg-
istry and is subject to all the inherent limitations. Although 
every effort was made to collect the data in a uniform and 
thorough manner, some measurement bias may have oc-
curred. Furthermore, device programming was not identical 
in all centres. Additionally, the relatively small number of 
patients limited our ability to identify predictors of appropriate 
and inappropriate ICD therapies. Another important concern 
is the deleterious psychological impact of ICD implantation 
on young patients. Anxiety and psychological distress are 
recognised to be more frequent in young ICD recipients; 
however, they were not assessed systematically in the study. 
Lastly, because genetic screening of LQTS genes is not reim-
bursed in Poland, data on LQTS genotype were available only 
in a minority of patients and were not included in the study.
In conclusion, although ICD proved to be effective in 
45% of LQTS patients, this therapy was associated with high 
complication rates. In our opinion, the present study does not 
support a more liberal use of ICD in LQTS patients. By provid-
ing explicit data regarding the risks and benefits of long-term 
ICD therapy, our findings may be useful in informing patients 
and physicians who need to make decisions regarding ICD 
implantation, particularly in the primary prevention of SCD. 
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WHAT IS NEW?
No randomised clinical trial has ever been conducted on patients with implantable cardioverter-defibrillators (ICDs) and 
long QT syndrome (LQTS), thus registry data are still of importance to help in risk stratification and to improve treat-
ment options. In our multicentre study of primary and secondary prevention in LQTS patients, risk factors for appropri-
ate ICD therapy were: recurrent syncope despite b-blockers before ICD implantation, pacemaker therapy before ICD 
implantation, a single-chamber ICD, and noncompliance to b-blockers. Inappropriate therapies were triggered by fast 
sinus rhythm, atrial fibrillation, and T-wave oversensing, however, no predictors of inappropriate shocks were identified. 
Importantly, in the majority of patients at least one adverse event occurred. By providing data regarding the risk and 
benefit of ICD therapy, our findings may be useful in informing patients and physicians who need to make decisions 
regarding ICD implantation.
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